Karyopharm Therapeutics Inc. Securities Litigation

If you purchased a significant amount of shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI), you have certain options. Investors should register for updates.

 

Lawsuit Overview

Defendant:Karyopharm Therapeutics Inc.
Date Filed:July 23rd, 2019
Sector:Health Care
Industry:Major Pharmaceuticals

According to the Complaint, Karyopharm is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer and other major diseases. During the Class Period, Karyopharm's lead drug candidate was selinexor, an oral selective inhibitor of nuclear export for the treatment of cancer indications with significant unmet clinical need, initially to be used for the treatment of blood cancers.

The Complaint alleges that during the Class Period, Defendants falsely represented the safety and efficacy of selinexor. Specifically, the Complaint alleges Defendants' material misrepresentations and omissions center on Defendants' claims regarding results from clinical trials for selinexor's treatment of patients with certain types of blood cancer.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Karyopharm Therapeutics Inc.

 
First Identified Complaint

Allegheny County Employees' Retirement System, et al. v. Karyopharm Therapeutics Inc., et al.

Date Filed:July 23rd, 2019
Class Period Start:March 2nd, 2017
Class Period End:February 22nd, 2019
First Identified Complaint Filings
#Document TitleFiling Date